The global biopharma industry is facing intensifying scrutiny over drug pricing as governments and payers push back against rising healthcare costs. In Canadian Health systems, where public funding pl...
For all the scientific advances in drug development, clinical trials remain one of the most inefficient and fragile components of the system. Patient recruitment is slow and costly, retention rates ar...
Artificial intelligence has rapidly moved from a buzzword to a core component of modern drug development. From target identification and molecule design to clinical trial optimization, AI pr...
For decades, the pharmaceutical industry was built around the blockbuster model, developing medicines with broad indications capable of generating billions in annual revenue. These therapies, often de...
Canada’s biopharma sector is entering a defining phase where scientific ambition is increasingly intersecting with economic reality. Breakthroughs in gene therapies, precision medicine, and AI driven ...
Healthcare is undergoing a major cultural and commercial shift as patients become more informed, digitally connected, and actively involved in their care decisions. What was once a largely physician d...
Takeaways: AbbVie is doubling down on Canada as a discovery hub by becoming the founding sponsor of BioLabs University of Toronto, a ~40,000 sq. ft shared lab at MaRS t...
Quantum computing has become one of the most talked about emerging technologies in pharmaceutical research, promising computational capabilities far beyond the limits of classical systems. Supporters ...
Takeaways VUEWAY should help Bracco win share in Canada’s MRI contrast market by offering radiology departments a lower‑gadolinium option that still delivers high‑quality images, which is increa...
For decades, women’s health remained one of the most underfunded and underserved areas in healthcare despite representing half the global population. Many conditions affecting women received limited r...
